Costs associated with treatment of severe combined immunodeficiency—rationale for newborn screening in Sweden - 27/09/17
Doi : 10.1016/j.jaci.2016.10.043
Ann Gardulf, RN, PhD a, b 
, Jacek Winiarski, MD, PhD c, d, Moa Thorin, BSc a, b, Marianne Heibert Arnlind, RN, PhD, MPH e, Ulrika von Döbeln, MD, PhD f, Lennart Hammarström, MD, PhD a, b
, Jacek Winiarski, MD, PhD c, d, Moa Thorin, BSc a, b, Marianne Heibert Arnlind, RN, PhD, MPH e, Ulrika von Döbeln, MD, PhD f, Lennart Hammarström, MD, PhD a, b a Division of Clinical Immunology and Transfusion Medicine, Department of Laboratory Medicine, Karolinska Institutet, Huddinge, Stockholm, Sweden
b Jeffrey Modell Diagnostic and Research Centre for Primary Immunodeficiencies, Department of Laboratory Medicine, Karolinska Institutet, Huddinge, Stockholm, Sweden
c Astrid Lindgren Children's Hospital, Karolinska University Hospital, Huddinge, Stockholm, Sweden
d Division of Paediatrics, Department of Clinical Science Intervention and Technology, Karolinska Institutet, Karolinska University Hospital, Huddinge, Stockholm, Sweden
e Department of Learning, Informatics, Management and Ethics, Karolinska Institutet, Stockholm, Sweden
f Division of Molecular Metabolism, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
| The study was funded by the Jeffrey Modell Foundation, New York; the Swedish Research Council, Stockholm, Sweden; and research funds from Karolinska Institutet, Stockholm, Sweden. |
|
| Disclosure of potential conflict of interest: A. Gardulf, M. Thorin, and L. Hammarström receive research support from the Swedish Research Council and the Jeffrey Modell Foundation. U. von Döbeln provides expert testimony from Genzyme-Sanofi. The rest of the authors declare that they have no relevant conflicts of interest. |
© 2016
American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 139 - N° 5
P. 1713 - mai 2017 Retour au numéro
Article précédent
- Anaphylaxis after zoster vaccine: Implicating alpha-gal allergy as a possible mechanism
- Cosby A. Stone, Jonathan A. Hemler, Scott P. Commins, Alexander J. Schuyler, Elizabeth J. Phillips, R. Stokes Peebles, John M. Fahrenholz
- IgE and antiviral immune response in asthma
- Jonathan S. Tam, Mitchell H. Grayson
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?